Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2482825 | 0.87 | GRM5 (1.00) | GRM5LMNA | |
| SCHEMBL5924170 | 0.83 | GRM5 (1.00) | GRM5LMNA | |
| SCHEMBL5924104 | 0.81 | GRM5 (1.00) | GRM5LMNA | |
| SCHEMBL3677412 | 0.81 | GRM5 (0.80) | GRM5LMNA | |
| SCHEMBL14132974 | 0.80 | GRM5 (0.85) | GRM5LMNA | |
| SCHEMBL5924064 | 0.79 | GRM5 (1.00) | GRM5LMNA | |
| SCHEMBL14132564 | 0.79 | GRM5 (0.91) | GRM5LMNA | |
| SCHEMBL5924177 | 0.76 | GRM5 (0.85) | GRM5LMNA | |
| SCHEMBL30856473 | 0.76 | TSHR (0.51) | — | |
| SCHEMBL24157522 | 0.75 | CYP2C9 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4665215-A1 | IMPLANTABLE PRESSURE SENSOR DRIFT DETECTION | TC1 LLC (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | claimed |
| WO-2024172917-A1 | IMPLANTABLE PRESSURE SENSOR DRIFT DETECTION | TC1 LLC (US) | 2024-08-22 | — | — | WO | claimed |
| US-20240268687-A1 | IMPLANTABLE PRESSURE SENSOR DRIFT DETECTION | TC1 LLC | 2024-08-15 | — | — | US | claimed |
| WO-2024088712-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2024-05-02 | — | — | WO | claimed |
| EP-4113052-B1 | SEEKER DEVICE FOR MISSILE | THALES SA (FR) | 2024-02-14 | — | — | EP | claimed |
| CN-110826431-B | Monte Carlo-based visible light vein imaging method | 南京航空航天大学 | 2023-04-25 | — | — | CN | claimed |
| EP-4113052-A1 | SEEKER DEVICE FOR MISSILE | THALES (FR) | 2023-01-04 | — | — | EP | claimed |
| WO-2022272293-A1 | COMPOSITIONS AND METHODS FOR EFFICIENT RETRON PRODUCTION AND GENETIC EDITING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-29 | — | — | WO | claimed |
| US-20220358039-A1 | PHYSICAL ADDRESS PROXY (PAP) RESIDENCY DETERMINATION FOR REDUCTION OF PAP REUSE | Ventana Micro Systems Inc. | 2022-11-10 | — | — | US | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | disclosed |
| US-20260124436-A1 | SYSTEMS AND METHODS FOR TREATING PULMONARY HYPERTENSION | ARIA CV, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12583906-B2 | Actrii proteins and use in treating post-capillary pulmonary hypertension | ACCELERON PHARMA INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12539052-B2 | Reconstruction of electrocardiogram from photoplethysmogram signals | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2026-02-03 | — | — | US | disclosed |
| US-8853392-B2 | Benzamide mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120264784-A1 | METHODS OF TREATING ELEVATIONS IN MTOR SIGNALING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-10-18 | — | — | US | disclosed |
| EP-2496224-A1 | METHODS OF TREATING ELEVATIONS IN MTOR SIGNALING | Brown University (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011056849-A1 | METHODS OF TREATING ELEVATIONS IN MTOR SIGNALING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583906-B2 | Actrii proteins and use in treating post-capillary pulmonary hypertension | MYOF, FLT1, MYH2 | GRM5 4238/4885LMNA 396/4885 |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | GRM5, OPRL1, GRM1 | GRM5 1/4885LMNA 3538/4885 |
| US-12539052-B2 | Reconstruction of electrocardiogram from photoplethysmogram signals | TNNT2, TTK, PFKP | GRM5 4170/4885LMNA 1699/4885 |
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM3 | GRM5 1/4885LMNA 4804/4885 |
| US-20120264784-A1 | METHODS OF TREATING ELEVATIONS IN MTOR SIGNALING | MTOR, RPTOR, GRM1 | GRM5 13/4885LMNA 3805/4885 |
| US-20260124436-A1 | SYSTEMS AND METHODS FOR TREATING PULMONARY HYPERTENSION | TNNT2, NPPA, NPR1 | GRM5 4736/4885LMNA 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.